5) end-points, including efficacy outcomes [HbA1c, body weight, FPG, 2 h postprandial glucose (2 h PG), SBP, DBP, waist circumference, and lipid levels] and safety outcomes (hypoglycaemia, nausea, diarrhoea, vomiting, injection site-related events, urinary tract infection, genital infection etc.)
This FAQ does not replace professional medical advice
Risk ratios (RR) for MACE estimates according to direct (DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors against placebo) and indirect (DPP-4 inhibitors vs GLP-1RA or SGLT-2 inhibitors, and GLP-1RA vs SGLT-2 inhibitors) comparisons
La clave reside en la personalizacin y en el acceso equitativo a ambas innovaciones
By ensuring L-Lysine sufficiency, patients provide their B-cells with the necessary components to manufacture these critical defense molecules